Company’s 36-month beta value is 0.59.Analysts have differing opinions on the stock, with 9 analysts rating it as a “buy,” 9 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for CYTK is 116.73M, and currently, short sellers hold a 12.00% ratio of that floaft. The average trading volume of CYTK on June 27, 2025 was 2.05M shares.
CYTK) stock’s latest price update
The stock price of Cytokinetics Inc (NASDAQ: CYTK) has jumped by 2.42 compared to previous close of 33.11. Despite this, the company has seen a gain of 3.61% in its stock price over the last five trading days. globenewswire.com reported 2025-06-17 that SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2025 it granted stock options to purchase an aggregate of 83,583 shares of common stock and 56,334 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 11 employees, whose employment commenced in May and June, 2025, as a material inducement to their employment.
CYTK’s Market Performance
Cytokinetics Inc (CYTK) has experienced a 3.61% rise in stock performance for the past week, with a 11.07% rise in the past month, and a -22.28% drop in the past quarter. The volatility ratio for the week is 3.52%, and the volatility levels for the past 30 days are at 3.88% for CYTK.. The simple moving average for the past 20 days is 3.50% for CYTK’s stock, with a -24.97% simple moving average for the past 200 days.
Analysts’ Opinion of CYTK
Many brokerage firms have already submitted their reports for CYTK stocks, with Barclays repeating the rating for CYTK by listing it as a “Overweight.” The predicted price for CYTK in the upcoming period, according to Barclays is $55 based on the research report published on April 24, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see CYTK reach a price target of $86. The rating they have provided for CYTK stocks is “Buy” according to the report published on February 07th, 2025.
Stifel gave a rating of “Buy” to CYTK, setting the target price at $80 in the report published on January 22nd of the current year.
CYTK Trading at -0.88% from the 50-Day Moving Average
After a stumble in the market that brought CYTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.75% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYTK starting from Malik Fady Ibraham, who sale 2,000 shares at the price of $32.91 back on Jun 17 ’25. After this action, Malik Fady Ibraham now owns 140,610 shares of Cytokinetics Inc, valued at $65,820 using the latest closing price.
Blum Robert I, the President & CEO of Cytokinetics Inc, sale 5,000 shares at $33.80 during a trade that took place back on Jun 16 ’25, which means that Blum Robert I is holding 403,108 shares at $169,000 based on the most recent closing price.
Stock Fundamentals for CYTK
Current profitability levels for the company are sitting at:
- -29.43 for the present operating margin
- -13.6 for the gross margin
The net margin for Cytokinetics Inc stands at -32.01. The total capital return value is set at -0.51.
Based on Cytokinetics Inc (CYTK), the company’s capital structure generated 1.51 points at debt to capital in total, while cash flow to debt ratio is standing at -0.5. The debt to equity ratio resting at -2.97. The interest coverage ratio of the stock is -6.14.
Currently, EBITDA for the company is -493.48 million with net debt to EBITDA at -1.39. When we switch over and look at the enterprise to sales, we see a ratio of 248.06. The receivables turnover for the company is 9.55for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.99.
Conclusion
In a nutshell, Cytokinetics Inc (CYTK) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
